Clinical Significance of Preoperative Serum CEA, CA125, and CA19-9 Levels in Predicting the Resectability of Cholangiocarcinoma
Table 1
Relationship between clinical features and resectability of cholangiocarcinoma patients.
Features
Resectable ()
Unresectable ()
Total ()
value
Age (yr)
60.9 ± 7.7
63.7 ± 1 0.0
62.5 ± 9.1
Sex ()
0.172
Men
33
33
66
Women
17
29
46
Tumor location ()
0.029
Intrahepatic
4
12
16
Hilar
12
23
35
Distal
34
27
61
Differentiation ()
0.003
High
20
4
24
Moderate
22
6
28
Poor
8
12
20
Tumor diameter (cm)
2.3 ± 0.9
4.5 ± 1.6
3.5 ± 1.3
AJCC stage ()
0.000
I
2
0
2
II
41
3
44
III
7
17
24
IV
0
42
42
CEA (ng/mL)
5.0 ± 13.9
19.1 ± 69.2
12.8 ± 52.6
CA125 (U/mL)
15.3 ± 11.8
48.8 ± 58.7
33.9 ± 47.3
CA19-9 (U/mL)
257.5 ± 325.6
730.1 ± 527.5
519.1 ± 505.4
Total bilirubin (μmol/L)
187.1 ± 121.7
219.3 ± 174.9
204.9 ± 153.5
AJCC Cancer Staging Manual 7th edition. Patients were divided into the resectable and unresectable groups; some patients in the unresectable group were diagnosed according to imaging findings and therefore had no data on pathological stage or AJCC stage.
